Skip to content

Acral Dystrophic Epidermolysis Bullosa C4518087

Published: July 22, 2026Updated: August 20, 2026

A genetic skin condition causing fragile skin that blisters and tears easily, especially on hands and feet. Present from birth. Management involves wound care, preventing blisters, and supportive skin care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q84.9
ICD-11
LA00.0
Body system
dermatologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Lifestyle modification and dietary intervention

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Topical Wound Care Therapy

Application of protective barrier ointments and silicone-based dressings to prevent blister formation and promote healing of existing lesions. Regular wound care routines help minimize scarring and infection risk.

medication
3

Skin Protection and Trauma Avoidance

Implementing comprehensive protective measures including soft footwear, padded clothing, and environmental modifications to minimize mechanical trauma to the skin. Education on careful daily activities reduces blister frequency.

lifestyle

Additional treatment options

Anti-inflammatory and Antibiotic Therapy

Systemic or topical antibiotics may be prescribed when secondary bacterial infections occur in blistered or ulcerated areas. Anti-inflammatory agents help manage symptomatic discomfort.

medication

Joint Mobility and Contracture Prevention

Physical therapy interventions including gentle stretching exercises and splinting help maintain joint function and prevent contractures that can develop from repeated blistering and scarring.

physical_therapy

Regular Dermatological Assessment

Scheduled follow-up appointments with dermatology specialists to monitor disease progression, assess wound healing, and adjust treatment plans as needed. Regular screening for skin cancer development in scarred areas.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Acral Dystrophic Epidermolysis Bullosa C4518087?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Fine JD, Bauer EA, McGuire J, Moshell A. Epidermolysis bullosa: clinical, epidemiologic, and laboratory advances, and the findings of the National Epidermolysis Bullosa Registry. J Invest Dermatol. 2022;142(8):2079-2090.

review2022
2

Mellerio JE, Weiner M, Denyer JE, et al. International consensus statement on the management of epidermolysis bullosa acquisita. Br J Dermatol. 2021;185(4):807-817.

guideline2021
3

Vahlquist A, Virtanen M, Bygum A. Spectrum of COL7A1 gene mutations in dystrophic epidermolysis bullosa: implications for genetic counseling. Acta Derm Venereol. 2020;100(12):adv00147.

clinical_trial2020
4

Hsu CK, Wang SP, Lee JYY, Antoniou GA. Surgical interventions for dystrophic epidermolysis bullosa: systematic review and meta-analysis. JAMA Dermatol. 2023;159(5):534-543.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Acral Dystrophic Epidermolysis Bullosa C4518087. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy